NL-OMON47964已完成不适用
B cell monitoring in young and elderly healthy donors, young smokers, elderly smokers and patients with stable coronary artery disease - B cell monitoring in healthy donors, smokers and CAD patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy volunteers:
- •1. healthy male subjects (18-25 years or >60 years);
- •2. ability to participate, and willingness to give written informed consent and
- •to comply with the study restrictions.
- •3. BMI 18 - 28
- •4. non-smoking, elderly non-smoking for at least 15 years.
- •1. male subjects (18-25 years or >45 years)
- •2. ability to participate, and willingness to give written informed consent and
- •to comply with the study restrictions.
- •3. BMI 18 - 28
- •4. volunteers >45 years: smoking for at least 15 packyears, volunteers 18- 25
- •years: at least * pack a day for 6 months. , CAD patients:
- •1. male patients (>60 years) with proven stable atherosclerotic coronary artery
- •disease defined as having undergone a revascularization procedure followed by a
- •period of at least one year without signs or symptoms of coronary artery
- •2. having one of the following risk factors: high cholesterol, smoking,
- •diabetes, hypertension, or familiar risk.
- •3. ability to participate, and willingness to give written informed consent and
- •to comply with the study restrictions.
- •4. BMI 18 - 28
排除标准
- •healthy volunteers:
- •1. evidence of any active or chronic disease or condition (based on medical
- •history, a physical examination, and vital signs) that could, in the opinion of
- •the investigator, interfere with the study objectives;
- •2. evidence of any active or chronic disease or condition that affects the
- •immune system.
- •3. having one of the following risk factors for CAD: high cholesterol, smoking,
- •diabetes, hypertension, or familiar risk.
- •4. the use of any medication or vitamin/mineral/herbal/dietary supplement
- •within less than 5 half-lives prior to study participation is prohibited, if
- •the Investigator judges that it may interfere with the study objectives. The
- •use of paracetamol (up to 4 g/day) is allowed;
- •5. body weight < 50 kg; BMI <18 or >28.
- •6. subject is pregnant or breast feeding;
- •7. smoking or current substance abuse, including alcohol and drugs;
- •8. loss or donation of blood over 500 mL within three months prior to
- •participation;
- •9. unwillingness or inability to comply with the study protocol for any other
- •reason., Smokers:
- •1. evidence of any active or chronic disease or condition (based on medical
- •history, a physical examination, and vital signs) that could, in the opinion of
- •the investigator, interfere with the study objectives;
- •2. body weight < 50 kg; or BMI <18 or >35;
- •3. substance abuse, including alcohol and drugs;
- •4. loss or donation of blood over 500 mL within three months prior to
- •participation;
- •5. unwillingness or inability to comply with the study protocol for any other
- •reason., CAD patients:
- •1. evidence of any active or chronic disease or condition other than stable CAD
- •(based on medical history, a physical examination, and vital signs) that could,
- •in the opinion of the investigator, interfere with the study objectives;
- •2. evidence of any active or chronic disease or condition other than stable CAD
- •that affects the immune system.
- •3. body weight < 50 kg; BMI <18 or >28.
- •4. substance abuse, including alcohol and drugs;
- •5. loss or donation of blood over 500 mL within three months (males) prior to
- •participation;
- •6. unwillingness or inability to comply with the study protocol for any other
- •7. use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
研究者
相似试验
招募中
不适用
B cell monitoring in healthy donors, smokers and CAD patientscardiac arrestNL-OMON26137CHDR150
尚未招募
不适用
A study on the immunological response of Rituximab on primary CNS demyelinating disorders in terms of safety and efficacyCTRI/2020/05/025384INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH KOLKATA
已完成
不适用
Characterisation of Human B Cell Maturation in Response to VaccinationHepatitis BNCT03535779Imperial College London16
已完成
不适用
The function and composition of B cells in patients with Glioblastoma treated with and without Dexamethasone10029211GlioblastomaBrain TumorNL-OMON49155Vrije Universiteit Medisch Centrum20
Unknown
不适用
Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGMLymphoma, Large B-Cell, DiffuseNCT02364050Fondazione Italiana Linfomi - ETS1,300